Cargando…
Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841436/ https://www.ncbi.nlm.nih.gov/pubmed/27143846 http://dx.doi.org/10.2147/OPTH.S108314 |
| _version_ | 1782428394287267840 |
|---|---|
| author | Kaya, Abdullah |
| author_facet | Kaya, Abdullah |
| author_sort | Kaya, Abdullah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4841436 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Dove Medical Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-48414362016-05-03 Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” Kaya, Abdullah Clin Ophthalmol Letter Dove Medical Press 2016-04-18 /pmc/articles/PMC4841436/ /pubmed/27143846 http://dx.doi.org/10.2147/OPTH.S108314 Text en © 2016 Kaya. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| spellingShingle | Letter Kaya, Abdullah Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title | Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title_full | Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title_fullStr | Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title_full_unstemmed | Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title_short | Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| title_sort | comment on: “three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841436/ https://www.ncbi.nlm.nih.gov/pubmed/27143846 http://dx.doi.org/10.2147/OPTH.S108314 |
| work_keys_str_mv | AT kayaabdullah commentonthreeyearfollowupofranibizumabtreatmentofwetagerelatedmaculardegenerationinfluenceofbaselinevisualacuityandinjectionfrequencyonvisualoutcomes |